How does pregabalin work in the treatment of seizures?

Pregabalin exerts its anticonvulsant effect by binding with high affinity to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels in the central nervous system. This binding modulates calcium influx at the presynaptic nerve terminals, thereby reducing the release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. This decrease in neuronal excitability is the primary mechanism responsible for its therapeutic effects in treating seizures, neuropathic pain, and anxiety. Pregabalin is a structural derivative of the inhibitory neurotransmitter GABA but does not directly interact with GABA receptors.

A. Sodium channel blocker: This is the mechanism of action for other antiepileptic drugs like phenytoin, carbamazepine, and lamotrigine, not pregabalin.
C. AMPA receptor antagonist: This mechanism, which involves blocking a subtype of glutamate receptor, is characteristic of antiepileptics like perampanel.
D. GABA agonist: Although structurally similar to GABA, pregabalin does not bind to GABA-A or GABA-B receptors and does not enhance GABAergic transmission.
E. SV2A binder: Binding to the synaptic vesicle protein 2A (SV2A) is the unique mechanism of action for levetiracetam and brivaracetam.

1. U.S. Food and Drug Administration (FDA). (2023). LYRICA (pregabalin) capsules

oral solution

and extended-release tablets

for oral use. Prescribing Information. Pfizer Inc. Section 12.1

Mechanism of Action. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/021446s047

022488s026

207446s012lbl.pdf

2. Bockbrader

H. N.

Wesche

D.

Miller

R.

Chapel

S.

Janiczek

N.

& Burger

P. (2010). A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical Pharmacokinetics

49(10)

661–669. Page 662

Section "Mechanism of Action". https://doi.org/10.2165/11536200-000000000-00000

3. McKeage

K.

& Keam

S. J. (2009). Pregabalin: in the treatment of postherpetic neuralgia. Drugs & Aging

26(10)

883–892. Page 883

Abstract. https://doi.org/10.2165/11203430-000000000-00000